Scarica l'app Stockscreener
1.09
10.10%
0.10
Dopo l'orario di chiusura:
1.05
-0.04
-3.67%
Precedente Chiudi:
$0.99
Aprire:
$1.01
Volume 24 ore:
48,987
Relative Volume:
0.55
Capitalizzazione di mercato:
$6.43M
Reddito:
-
Utile/perdita netta:
$-13.32M
Rapporto P/E:
-0.1811
EPS:
-6.02
Flusso di cassa netto:
$-13.01M
1 W Prestazione:
-14.17%
1M Prestazione:
-8.40%
6M Prestazione:
-41.40%
1 anno Prestazione:
-41.40%
Intervallo 1D:
$0.9714
$1.11
Intervallo di 1 settimana:
$0.925
$1.28
Portata 52W:
$0.925
$2.6702
Plus Therapeutics Inc Stock (PSTV) Company Profile
Nome
Plus Therapeutics Inc
Settore
Industria
Telefono
737.255.7194
Indirizzo
4200 MARATHON BLVD., AUSTIN, TX
Confronta PSTV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
PSTV
Plus Therapeutics Inc
|
1.09 | 6.43M | 0 | -13.32M | -13.01M | -4.39 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Plus Therapeutics Inc Stock (PSTV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-01-25 | Iniziato | Ladenburg Thalmann | Buy |
| 2020-10-16 | Iniziato | Maxim Group | Buy |
Plus Therapeutics Inc Borsa (PSTV) Ultime notizie
Plus Therapeutics Presents Positive ReSPECT-LM Phase 1 - GlobeNewswire
Plus Therapeutics Reports Promising 88% Response Rate in Phase 1 Cancer Treatment Trial - StockTitan
PSTV stock touches 52-week low at $1.12 amid market challenges - Investing.com UK
Candel Therapeutics Stock Surges Over 100%Here's Why - Yahoo Finance
Candel Therapeutics Announces CAN-2409 Achieved Primary - GlobeNewswire
Plus Therapeutics (NASDAQ:PSTV) Price Target Lowered to $19.00 at Ascendiant Capital Markets - Defense World
Roche commences tender offer for all shares of Poseida Therapeutics, Inc. for $9.00 per share in cash, plus a non-tradeable contingent value right for up to $4.00 per share in cash - The Manila Times
Plus Therapeutics to Showcase ReSPECT-LM Phase 1 Interim - GlobeNewswire
Plus Therapeutics to Present Crucial Phase 1 Data for Novel Brain Cancer Treatment at Major Symposium - StockTitan
Plus Therapeutics Expands Strategic Agreement with Telix - GlobeNewswire
Plus Therapeutics Secures 5-Year Supply Deal for Key Cancer Treatment Radioisotope - StockTitan
HC Wainwright Reiterates Buy Rating for Plus Therapeutics (NASDAQ:PSTV) - Defense World
Plus Therapeutics shares hold price target, buy rating on positive study results - Investing.com
CNSide Diagnostics reports data from trial of CNSide CSF Assay in LM diagnosis - Medical Device Network
Plus Therapeutics' Cancer Drug Shows 93% Response Rate in Phase 1 Trial | PSTV Stock News - StockTitan
PSTVPLUS THERAPEUTICS, Inc. Latest Stock News & Market Updates - StockTitan
PSTV stock touches 52-week low at $1.14 amid market challenges - Investing.com UK
Plus Therapeutics to Present Positive FORESEE Clinical - GlobeNewswire
Plus Therapeutics' CNSide Trial Shows 90% Success in Cancer Treatment Decisions | PSTV Stock News - StockTitan
Plus Therapeutics to Present Multi-Institutional Experience - GlobeNewswire
Plus Therapeutics Reveals Breakthrough LM Cancer Biomarker Study with 88% Detection Rate | PSTV Stock News - StockTitan
Citius Pharmaceuticals, Inc. (NASDAQ:CTXR) Short Interest Update - Defense World
Jones Trading cuts PSTV stock target, maintains Buy rating on Q3 earnings - Investing.com
Earnings call: Plus Therapeutics reports progress and financials for Q3 2024 - Investing.com
Contrasting Plus Therapeutics (NASDAQ:PSTV) and Inspira Technologies Oxy B.H.N. (NASDAQ:IINN) - Defense World
Plus Therapeutics Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance
Plus: Q3 Earnings Snapshot - New Haven Register
Plus Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Plus Therapeutics Inc (PSTV) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Plus Therapeutics Advances Radiotherapeutics in Q3 2024 - TipRanks
Plus Therapeutics Advances Cancer Drug Pipeline, Reports $4.4M Grant Revenue in Q3 | PSTV Stock News - StockTitan
Organogenesis (ORGO) Tops Q3 Earnings and Revenue Estimates - Yahoo Finance
Leptomeningeal Metastases Clinical Trials 2024: FDA - openPR
Undercovered Dozen: Asbury Automotive, Globalstar, Northland Power, Aquestive Therapeutics - Seeking Alpha
Sitravatinib Plus Nivo-Ipi Appears Safe, Active in ccRCC - Cancer Therapy Advisor
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Plus Therapeutics partners with SpectronRx for cancer therapy - Investing.com India
Plus Therapeutics partners with SpectronRx for cancer therapy By Investing.com - Investing.com UK
Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership - GlobeNewswire
Plus Thera teams up with SpectronRx for radiotherapy production - The Pharma Letter
Plus Therapeutics to Announce Third Quarter Financial Results and Host Conference Call on November 14, 2024 - GlobeNewswire
Plus Therapeutics (PSTV) Sets Q3 2024 Earnings Call for November 14 | PSTV Stock News - StockTitan
Plus Therapeutics granted extension by Nasdaq - Investing.com
Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca - The Globe and Mail
Plus Therapeutics Showcases Leptomeningeal Metastases - GlobeNewswire
Simulations Plus, Inc. (NASDAQ:SLP) Receives $56.00 Consensus Price Target from Analysts - Defense World
Metastatic Colorectal Cancer Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Daiichi Sankyo Company, Mirati Therapeutics, Apollomics - Barchart
Evaluating Immunotherapy as Systemic Therapy Plus RT in Early-Stage NSCLC - Cancer Network
Colorectal Cancer Pipeline Overview 2024: FDA Approvals and Key Companies involved by DelveInsight | Novartis, Pharma Oncology, Purple Biotech Ltd, Plus Therapeutics, Processa Pharma - The Globe and Mail
Plus Therapeutics Inc Azioni (PSTV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Plus Therapeutics Inc Azioni (PSTV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Hawkins Richard J | Director |
Sep 12 '24 |
Buy |
1.35 |
6,285 |
8,512 |
11,188 |
| Petersen Greg | Director |
Sep 11 '24 |
Buy |
1.35 |
12,500 |
16,875 |
48,921 |
| Clowes Howard | Director |
Sep 11 '24 |
Buy |
1.34 |
5,000 |
6,681 |
26,497 |
| HEDRICK MARC H | Chief Executive Officer |
Sep 10 '24 |
Buy |
1.23 |
8,000 |
9,839 |
20,425 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
Sep 10 '24 |
Buy |
1.27 |
4,098 |
5,204 |
9,815 |
| Sims Andrew John Hugh MacIntyr | Chief Financial Officer |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
5,717 |
| HEDRICK MARC H | Chief Executive Officer |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
12,425 |
| Petersen Greg | Director |
May 08 '24 |
Buy |
2.04 |
12,255 |
25,000 |
36,421 |
| Clowes Howard | Director |
May 08 '24 |
Buy |
2.04 |
9,804 |
20,000 |
21,497 |
| Hawkins Richard J | Director |
May 08 '24 |
Buy |
2.04 |
4,902 |
10,000 |
4,903 |
2.88%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):